Zura Bio (NASDAQ:ZURA) Stock

Zura Bio

Zura Bio Ltd is a multi-asset clinical-stage biotechnology company focused on developing novel medicines for immune and inflammatory disorders.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AIXI

ALVO

BTAI

CRCT

IRON

LILM

LQDA

NERV

OLMA

XERS

ZURA

U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Thursday. Here are some big stocks recording losses in today’s session.


BioXcel Therapeutics, Alvotech And Other Big Stocks Moving Lower On Thursday

Short Ideas

BHVN

IMTX

NAUT

VALN

The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies.

Top 5 Health Care Stocks That May Crash This Month

Biotech

Health Care

General

Shares of Zura Bio Ltd (NASDAQ: ZURA) shares are trading lower Wednesday, possibly on profit-taking after the stock rallied roughly more than 35% Tuesday afternoon. 

What&#39;s Going On With Zura Bio Stock Today

Zura Bio Limited - Class A Ordinary shares

Zura Bio Ltd

Watts Water Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WTS#NYSE">WTS</a>) reported quarterly earnings of $2.05 per share which beat the analyst consensus estimate of $1.91 by 7.33 percent. This is a 4.06 percent increase over earnings of $1.97 per share from the same period last year. The company reported quarterly sales of $540.400 million which beat the analyst consensus estimate of $537.260 million by 0.58 percent. This is a 1.30 percent decrease over sales of $547.500 million the same period last year.

Earnings

Earnings Beats

Watts Water Technologies Q4 2024 Adj. EPS $2.05 Beats $1.91 Estimate, Sales $540.400M Beat $537.260M Estimate

Middlefield Banc Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBCN#NASDAQ">MBCN</a>) today announced that its Board of Directors declared a quarterly cash dividend of $0.21 per common share, representing a 5% increase from the 2024 fourth quarter dividend. The 2025 first-quarter dividend is payable on March 14, 2025, to shareholders of record on February 28, 2025.

Dividends

MBCN

Middlefield Banc Corp. Announces Increase In Quarterly Dividend From $0.20 To $0.21 Per Share

Unitil FY24 Adjusted EPS $2.97, Up $0.15 From 2023

Offerings

HESM

Hess Midstream Announces 10M Class A Shares Public Offering

APP MOVES UP OVER 9 POINTS AT ITS HIGH
<figure class="wp-block-image size-full"><img loading="lazy" decoding="async" width="795" height="627" src="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/10211358/Screen-Shot-2025-02-10-at-4.20.54-PM.png" alt="" class="wp-image-5649" srcset="https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/10211358/Screen-Shot-2025-02-10-at-4.20.54-PM.png 795w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/10211358/Screen-Shot-2025-02-10-at-4.20.54-PM-300x237.png 300w,https://contributor-assets.benzinga.com/wp-content/uploads/2025/02/10211358/Screen-Shot-2025-02-10-at-4.20.54-PM-768x606.png 768w" sizes="(max-width: 795px) 100vw, 795px" /></figure>
Applovin, Inc. (APP) today experienced a Power Inflow, a significant event for those who follow where smart money goes and value order flow analytics in their trading decisions. 
Today, at 10:09 AM on February 10th, a significant trading signal occurred for Applovin Inc. (APP) as it demonstrated a Power Inflow at a price of $378.40. This indicator is crucial for traders who want to know directionally where institutions and so-called "smart money" moves in the market. They see the value of utilizing order flow analytics to guide their trading decisions. The Power Inflow points to a possible uptrend in Applovin&#8217;s stock, marking a potential entry point for traders looking to capitalize on the expected upward movement. Traders with this signal closely watch for sustained momentum in Applovin&#8217;s stock price, interpreting this event as a bullish sign.
Signal description
Order flow analytics, aka transaction or market flow analysis, separate and study both the retail and institutional volume rate of orders (flow). It involves analyzing the flow of buy and sell orders, along with size, timing, and other associated characteristics and patterns, to gain insights and make more informed trading decisions. This particular indicator is interpreted as a bullish signal by active traders.&nbsp;
The Power Inflow occurs within the first two hours of the market open and generally signals the trend that helps gauge the stock&#8217;s overall direction, powered by institutional activity in the stock, for the remainder of the day.&nbsp;
By incorporating order flow analytics into their trading strategies, market participants can better interpret market conditions, identify trading opportunities, and potentially improve their trading performance. But let's not forget that while watching smart money flow can provide valuable insights, it is crucial to incorporate effective risk management strategies to protect capital and mitigate potential losses. Employing a consistent and effective risk management plan helps traders navigate the uncertainties of the market in a more controlled and calculated manner, increasing the likelihood of long-term success
If you want to stay updated on the latest options trades for APP, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts. 
<a href="https://benzinga.com/apis?_gl=1&#x2A;1hlgn5i&#x2A;_ga&#x2A;MTY1NjE2NTYxMi4xNzE0NzQ4MTAy&#x2A;_ga_V7ZK73W7N0&#x2A;MTcxNDc0ODEwMi4xLjEuMTcxNDc0ODQyOC4wLjAuMA..">Market News and Data brought to you by Benzinga APIs</a> and include firms, like&nbsp; &nbsp; <a href="https://www.tradepulse.net">https://www.tradepulse.net</a>&nbsp; which are responsible for parts of the data within this article. 
&#xA9; 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
After Market Close UPDATE:
The price at the time of the Power Inflow was $378.40. The returns on the High price ($387.96) and Close price ($384.59) after the Power Inflow were respectively 2.5% and 1.6%. That is why it is important to have a trading plan that includes Profit Targets and Stop Losses that reflect your risk appetite. In this case, the high of the day and close were close but that is not always the case
Past Performance is Not Indicative of Future Results

Equities

Technicals

TRADEPULSE POWER INFLOW ALERT: APPLOVIN (APP), REVERSES EARLY WEAKNESS AND CLIMBS 2.5% AFTER ALERT FROM TRADEPULSE

The mission, Rocket Lab's ninth launch for BlackSky overall, will launch from Rocket Lab Launch Complex 1 in New Zealand in February.
Rocket Lab USA, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RKLB#NASDAQ">RKLB</a>) ("Rocket Lab" or "the Company"), a global leader in launch services and space systems, today announced it will soon launch a satellite on a dedicated Electron mission, the first of a bulk order of multiple missions for real-time space-based intelligence company BlackSky (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BSKY#NYSE">BSKY</a>).
The mission, named "Fasten Your Space Belts", will launch from Rocket Lab's private orbital launch site, Rocket Lab Launch Complex 1, in New Zealand during a launch window that opens on February 18th UTC. The mission will launch the first Gen-3 satellite in BlackSky's mid-inclination, Earth-imaging constellation to a circular 470km orbit. The mission is the ninth launch for BlackSky since 2019, making Rocket Lab the most prolific launch provider for BlackSky's constellation to date.
Rocket Lab founder and CEO, Sir Peter Beck, says: "Electron is a trusted and reliable constellation builder for companies like BlackSky, allowing them to be in control of how, when, and where to deploy their constellation. BlackSky is one of our earliest and longest-standing commercial satellite customers, and it's great to be heading back to the pad with them once again to continue to advance and expand their constellation."

BlackSky Technology Inc. Class A Common Stock

BKSY

BSKY

RKLB

Rocket Lab Announces It Will Soon Launch A Satellite On A Dedicated Electron Mission, The First Of A Bulk Order Of Multiple Missions For BlackSky From Rocket Lab Launch Complex 1 In New Zealand In February

LegalZoom Acquires Formation Nation To Enhance Small Business Services; Terms Not Disclosed

Energy Servs of America (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ESOA#NASDAQ">ESOA</a>) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.10 by 50 percent. This is a 58.33 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $100.65 million which beat the analyst consensus estimate of $85.30 million by 17.99 percent. This is a 11.63 percent increase over sales of $90.16 million the same period last year.

Earnings Misses

ESOA

Energy Servs of America Q1 EPS $0.05 Misses $0.10 Estimate, Sales $100.65M Beat $85.30M Estimate

Bank of N.T Butterfield Q4 2024 Core EPS $1.34 Beats $1.17 Estimate

Tapestry (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) has outperformed the market over the past 5 years by 9.68% on an annualized basis producing an average annual return of 22.03%. Currently, Tapestry has a market capitalization of $18.42 billion. 
Buying $1000 In TPR: If an investor had bought $1000 of TPR stock 5 years ago, it would be worth $2,741.94 today based on a price of $79.05 for TPR at the time of writing.
<h3>Tapestry's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1739223027_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$1000 Invested In Tapestry 5 Years Ago Would Be Worth This Much Today

FLNC

Trading Halt: Halt status updated at 4:30:00 PM ET: Quotation Resumption: News and Resumption Times

WIIM

CoreCivic shares are trading lower after the company issued FY25 FFO guidance below estimates.

A group of investors led by the world's richest person Elon Musk has made a $97.4-billion offer to acquire control of OpenAI, the nonprofit AI giant Musk once co-founded.
What Happened: Musk, who has sued OpenAI as the company attempts to transition to a for-profit structure, previously founded the company with Sam Altman, Greg Brockman and several other individuals.
Musk put in capital to the company before leaving in 2018 over a disagreement regarding its direction. 
The Wall Street Journal <a href="https://www.wsj.com/tech/elon-musk-openai-bid-4af12827?mod=latest_headlines">reports </a>Monday that Musk is leading a group bidding $97.4-billion to take control of the nonprofit that controls OpenAI.
"It's time for OpenAI to return to the open-source, safety-focused force for good it once was," Musk said in a statement provided by his attorney Marc Toberoff. &#8220;We will make sure that happens."
Toberoff told the Wall Street Journal the bid for the nonprofit that controls OpenAI was submitted to OpenAI's board of directors Monday.
After Musk left, the company created a for-profit subsidiary that helped the company raise money from other investors including Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>).
Altman is pushing to make OpenAI a for-profit company, which could give him an opportunity for an equity stake in the company and increase his wealth.
Among the investors in the bid for OpenAI control include Musk's AI company xAI, Valor Equity Partners, Vy Capital, 8VC, Baron Capital and Atreides Management.
Altman appeared to dismiss the buyout offer in a tweet Monday. 
&#8220;No thank you but we will buy twitter for $9.74 billion if you want,&#8221; Altman <a href="https://x.com/sama/status/1889059531625464090">tweeted</a>. 
Read Also: <a href="https://www.benzinga.com/24/11/42022920/sam-altman-slams-elon-musks-left-wing-bias-claims-over-chatgpt-responds-to-grok-vs-gpt-debate-with-bold-remarks-but-tesla-ceo-says-swindly-sam-is-at-it-again">OpenAI Co-Founders, Now Rivals Sam Altman And Elon Musk Clash Over ChatGPT And xAI&#8217;s Grok Chatbots Again</a>
Why It's Important: News of the bid has raised questions to what this could mean for Altman's push for a for-profit company and whether xAI and OpenAI could be combined if the bid goes through.
Toberoff said Musk and the investor group are prepared to match higher bids in the process to value the nonprofit company.
"If Sam Altman and the present OpenAI Inc. Board of Directors are intent on becoming a fully for-profit corporation, it is vital that the charity be fairly compensated for what its leadership is taking away from it: control over the most transformative technology of our time," Toberoff said.
Musk and Altman have battled publicly in recent months. Musk recently said Altman and other investors in Project Stargate didn't have the funds for their announced venture.
OpenAI was<a href="https://www.benzinga.com/news/24/10/41149788/openai-valuation-soars-to-157b-in-latest-funding-round"> valued at $157 billion </a>in a funding round in October 2024. A recent report said OpenAI was also considering a funding round that could value the company at $300 billion.
Musk's xAI <a href="https://www.benzinga.com/24/11/42022077/elon-musks-xai-seeks-6b-at-50b-valuation-to-acquire-100k-nvidia-chips-for-memphis-data-center">was valued at </a>$50 billion in November 2024.
Musk is the world's richest person, with wealth of $402 billion, according to <a href="https://www.bloomberg.com/billionaires/">Bloomberg</a>. It is unknown how much of his personal fortune Musk put into the bid and what the source of his funds were. Musk previously sold a portion of his Tesla shares to help fund his $44-billion acquisition of Twitter in 2022.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/01/43214529/elon-musk-accuses-openai-ceo-sam-altman-of-lying-over-10b-equity-what-a-liar">Elon Musk Accuses OpenAI CEO Sam Altman Of Lying Over $10B Equity: &#8216;What A Liar&#8217;</a></li>
</ul>
Elon Musk and Sam Altman photos via Shutterstock.

Tech

MSFT

Elon Musk Co-Founded OpenAI, Now He's Bidding $97.4B To Take Back The Company

Guidance

CoreCivic Sees FY25 FFO $1.37-$1.50 Vs $1.77 Estimate

Illinois Workers Secure Major Wage Increases, Improved Benefits
LINCOLN, Ill., Feb. 10, 2025 /PRNewswire/ -- More than 100 Sysco drivers and warehouse workers represented by Teamsters Local 916 have overwhelmingly ratified a new four-year collective bargaining agreement, locking in significant wage increases and major improvements to benefits.
"Our members made it clear to management that they were ready to fight for what they deserved," said Justin Shaffer, a Local 916 business agent and lead negotiator. "Their unity and determination delivered a game-changing contract that raises standards across the board."
The new agreement includes a 36 percent wage increase, maintaining an excellent Teamsters health care plan at a now lower cost, and enhancements to seniority rights, vacation time, and sick leave.

Contracts

Management

Sysco Teamsters Overwhelmingly Ratify New Contract; Agreement With Sysco Includes 36% Wage Increase

Universal Sees Prelim Q3 EPS $2.27; Sales $937.2M

Jefferies analyst Maury Raycroft maintains Compass Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPX#NASDAQ">CMPX</a>) with a Buy and raises the price target from $7 to $8.

Price Target

Analyst Ratings

CMPX

Jefferies Maintains Buy on Compass Therapeutics, Raises Price Target to $8

Hamilton Lane intends to use the proceeds from the sale of its shares to settle in cash exchanges of membership units in Hamilton Lane Advisors, L.L.C. held by certain of its members. Hamilton Lane will not receive any proceeds from the sale of shares by the selling stockholder. &nbsp;

HLNE

Hamilton Lane Commences Public Offering Of 1.57M Class A Shares, In The Aggregate, To Be Sold By Company And A Selling Stockholder

Astera Labs Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) reported financial results for the fourth quarter after the market close on Monday. Here&#8217;s a rundown <a href="https://www.benzinga.com/pressreleases/25/02/g43607942/astera-labs-announces-financial-results-for-the-fourth-quarter-of-fiscal-year-2024">of the report</a>.
Q4 Earnings: Astera Labs reported fourth-quarter revenue of $141.1 million, beating analyst <a href="https://www.benzinga.com/calendars/earnings">estimates</a> of $127.98 million. The semiconductor-based connectivity solutions company reported adjusted fourth-quarter earnings of 37 cents per share, beating analyst estimates of 26 cents per share, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. 
Astera Labs is a supplier of connectivity solutions for several tech giants<a href="https://www.benzinga.com/news/24/10/41240051/astera-labs-stock-jumps-after-the-bell-whats-happening"> including Nvidia</a>. Total revenue was up 179% on a year-over-year basis and up 25% quarter-over-quarter. Gross margin came in at 74%. The company ended the quarter with cash and cash equivalents of $79.55 million.
&#8220;The revenue growth in 2024 was largely driven by Aries PCIe Retimer products, with Taurus Smart Cable Modules for Ethernet coming in strongly in Q4,&#8221; said Jitendra Mohan, CEO of Astera Labs.
&#8220;We expect 2025 to be a breakout year as we enter a new phase of growth driven by revenue from all four of our product families to support a diverse set of customers and platforms. This includes our flagship Scorpio Fabric products for head-node PCIe connectivity and backend AI accelerator scale-up clustering.&#8221;
See Also: <a href="https://www.benzinga.com/25/02/43605813/oil-prices-energy-stocks-jump-as-gaza-ceasefire-risks-collapse-on-rising-hamas-israel-tensions">Oil Prices, Energy Stocks Jump As Gaza Ceasefire Risks Collapse On Rising Hamas-Israel Tensions</a>
Guidance: Astera Labs expects first-quarter revenue to be in the range of $151 million to $155 million versus estimates of $134.25 million. The company anticipates adjusted earnings of 28 cents to 29 cents per share in the first quarter.
Management will hold a conference call to further discuss the quarter with investors and analysts at 4:30 p.m. ET.
ALAB Price Action: <a href="http://benzinga.com/quote/alab">Astera Labs shares</a> were down 4.35% after hours, trading at $98.77 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

ALAB

Astera Labs Q4 Earnings: Revenue Beat, EPS Beat, 2025 Expected To Be A 'Breakout Year' And More

Air Transport Services Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATSG#NASDAQ">ATSG</a>) ("ATSG" or the "Company"), a global leader in medium widebody freighter aircraft leasing, air transport operations, and support services, today announced that its stockholders voted to approve the proposed merger with Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, at a special meeting of the Company's stockholders.

ATSG

Air Transport Services Group Stockholders Approve Proposed Merger With Stonepeak

Press Releases

Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors

Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants

Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants

Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights

Zura Bio to Present at Three Upcoming Investor Conferences in September

Zura Bio to Participate in Two Upcoming Investor Conferences in November

Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates

Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis

Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference

Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis

Comments

Zura Bio

Loading...

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga